Adiponectin in patients with chronic kidney disease.
Adiponectin is one of many so called "adipokines"--cytokines, chemokines, growth factors, and complement proteins secreted by adipose tissue--that can affect the function of other organs. This antiatherogenic and insulin-sensitizing polypeptide is eliminated from the circulation mostly by the kidneys. Thus, in patients with chronic kidney disease, adiponectin accumulates in the circulation; its plasma concentration is approximately three times higher in end stage kidney disease than in healthy subjects. As no biological consequences of these unusually high adiponectin concentrations have been demonstrated, this polypeptide cannot be considered as a uremic toxin. On the contrary, inadequately low instead of high plasma adiponectin concentration is recognized as a new nontraditional risk factor of cardiovascular morbidity and mortality in these patients. This review summarizes the causes and clinical consequences of adiponectin accumulation in the circulation of patients with chronic kidney disease.
Adamczak
Marcin
M
Department of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Silesia, Katowice, Poland.
Chudek
Jerzy
J
Wiecek
Andrzej
A
D052242:Adiponectin / Q000502:physiology*; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology* / Q000378:metabolism / Q000628:therapy*
D052242:Adiponectin